As principal investigator on a variety of pharmacoeconomic and pharmacoepidemiology studies over the past 15 years, Alex, has led a wide range of research projects that have included cost-effectiveness models, budget impact models, retrospective database analyses, international surveys, literature reviews, and meta-analyses. She has extensive experience in design and conduct of modeling projects across numerous therapeutic areas including Alzheimer’s disease, diabetes, multiple sclerosis, pain management, Parkinson disease, schizophrenia, stroke, smoking cessation, ulcerative colitis, and pacemaker devices. She also has significant experience of working with less extensively studied rare diseases such as acromegaly, cystic fibrosis, cystinosis, Fabry disease, Gaucher disease, interstitial pulmonary fibrosis, refractory nontuberculous mycobacterial (NTM) lung disease, Pompe disease, and thalassemia. Alex has also worked on translating models into computer interfaces used for marketing and educational purposes, and in developing models that can be adapted for use in different countries. She has published and presented extensively and has been an author on 55 publications in refereed journals.
Prior to joining Evidera, Alex was employed by Caro Research, until its acquisition by UBC in 2007. She also worked in regulatory affairs for nine years with Glaxo and practiced as a clinical pharmacist for five years in the UK National Health Service. Alex earned her bachelor of pharmacy degree (1st Class Honors) from Bath University, and remains a registered pharmacist in the UK (Member of the Royal Pharmaceutical Society of Great Britain). She completed her master of science degree in clinical pharmacy at the London School of Pharmacy, and holds a diploma in regulatory affairs from the British Institute of Regulatory Affairs and Cardiff University. Alex received a PhD from the School of Pharmacy at the University of Rhode Island.